Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cintas Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Cintas Corporation trades at $180.27 (market cap $71.88B). The key difference: Cintas Corporation is the larger of the two by market cap, and Cintas Corporation pays a 1% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CTAS | |
|---|---|---|
Market Cap | $39.89B | $71.88B |
Sector | Health | Industrials |
52-Week High | $491.22 | $226.27 |
52-Week Low | $278.09 | $163.55 |
Enterprise Value | $38.15B | $74.62B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Cintas (CTAS) trades at $179.64, up 1.1% on the day, with a bullish technical signal and strong fundamentals including 17.57% net margin and consistent revenue growth to $10.34B in 2025. The stock shows robust cash flow from operations at $2.17B and has beaten earnings estimates in recent quarters. Recent news highlights upcoming Q4 2026 earnings and recognition as a top workplace, supporting positive sentiment.
Outlook remains favorable with a consensus price target of $212.50, though high valuation multiples (P/E 37.9) and competitive pressures pose risks. Earnings growth and market share expansion are key catalysts, but investors should monitor debt levels and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
